Quadratus Lumborum BlockNCT07850596
Quadratus Lumborum Block, Transversus Abdominis Plane Block, and Erector Spinae Block in Pediatric Abdominal Surgery
A study testing Quadratus lumborum (QL) block, Transversus abdominis plane (TAP) block and Erector spinae plane (ESP) block in people with Quadratus Lumborum Block and Transversus Abdominis Plane Block, run by Menoufia University at 1 site in Egypt.
Trial summary
The aim of this study is to compare the analgesic efficacy and safety of Quadratus Lumborum (QL), Transversus Abdominis Plane (TAP), and Erector Spinae Plane (ESP) blocks in pediatric abdominal surgery. Read more about this study
- Who is it for?
- Ages 3 to 12 years
- Conditions the study is for
- Quadratus Lumborum Block, Transversus Abdominis Plane Block, Erector Spinae Plane Block
- What is being tested?
- Quadratus lumborum (QL) block, Transversus abdominis plane (TAP) block and Erector spinae plane (ESP) block
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Jan 2025to 1 Jun 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 3 to 12 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- Children aged from 3 to12 years.
- Both sexes.
- American Society of Anesthesiologists (ASA) Physical Status I-II.
- Scheduled for pediatric abdominal surgery.
Who cannot join
- Allergy or contraindication to bupivacaine or dexmedetomidine.
- Coagulopathy.
- Local infection at the site of the block.
- Neurological or psychiatric disorders affecting pain perception.
- Refusal of the regional technique by parents/guardians.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Comparing Quadratus Lumborum Block, Transversus Abdominis Plane Block, and Erector Spinae Block in Pediatric Abdominal Surgery
The aim of this study is to compare the analgesic efficacy and safety of Quadratus Lumborum (QL), Transversus Abdominis Plane (TAP), and Erector Spinae Plane (ESP) blocks in pediatric abdominal surgery.
Read the detailed description
Advances in perioperative care of children continue to be made with increasing evidence-based practice for postoperative analgesia. However, moderate to severe pain is still experienced by up to 40% of hospitalized children and specific high-risk populations or types of surgery continue to present challenges.
Transversus abdominis plane (TAP) block involves the injection of local anesthesia (LA) in between the transversus abdominis (TA) and internal oblique (IO) muscles.
The Erector Spinae Plane (ESP) block is most often performed using an in-plane ultrasound-guided technique. It is a paraspinal fascial plane block in which the needle placement is between the erector spinae muscle and the thoracic transverse processes, and a local anesthetic is administered, blocking the dorsal and ventral rami of the thoracic and abdominal spinal nerves.
- Conditions
- Quadratus Lumborum Block, Transversus Abdominis Plane Block, Erector Spinae Plane Block, Pediatric, Abdominal Surgery
- Being tested
- Quadratus lumborum (QL) block, Transversus abdominis plane (TAP) block, Erector spinae plane (ESP) block
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Quadratus lumborum (QL) blockDrug
Also called Bupivacaine 0.25% (0.5 ml/kg) + dexmedetomidine 0.5 mcg/kg
Patients received quadratus lumborum (QL) block with bupivacaine 0.25% (0.5 ml/kg) + dexmedetomidine 0.5 mcg/kg.
Transversus abdominis plane (TAP) blockDrug
Also called Bupivacaine 0.25% (0.5 ml/kg) + dexmedetomidine 0.5 mcg/kg
Patients received transversus abdominis plane (TAP) block with bupivacaine 0.25% (0.5 ml/kg) + dexmedetomidine 0.5 mcg/kg.
Erector spinae plane (ESP) blockDrug
Also called Bupivacaine 0.25% (0.5 ml/kg) + dexmedetomidine 0.5 mcg/kg
Patients received erector spinae plane (ESP) block with bupivacaine 0.25% (0.5 ml/kg) + dexmedetomidine 0.5 mcg/kg.
| Study group | Role | What they receive |
|---|---|---|
| QL Group | Experimental | Patients received quadratus lumborum (QL) block with bupivacaine 0.25% (0.5 ml/kg) + dexmedetomidine 0.5 mcg/kg. Receives: Drug: Quadratus lumborum (QL) block |
| TAP group | Experimental | Patients received transversus abdominis plane (TAP) block with bupivacaine 0.25% (0.5 ml/kg) + dexmedetomidine 0.5 mcg/kg Receives: Drug: Transversus abdominis plane (TAP) block |
| ES Group | Experimental | Patients received erector spinae plane (ESP) block with bupivacaine 0.25% (0.5 ml/kg) + dexmedetomidine 0.5 mcg/kg. Receives: Drug: Erector spinae plane (ESP) block |
What is being measured
The primary outcome is the main question the study is designed to answer.
Degree of pain
Degree of pain will be assessed using Wong-Baker FACES for the first 24 hours postoperative at 4, 8,12,16 and 24 hours postoperatively.
Wong-Baker FACES Pain Scale, which utilizes a series of 6 faces increasing in pain severity may be used to facilitate communication and assist in pain assessment .
Measured: 24 hours postoperatively
Secondary outcomes (8)
Total fentanyl consumption
If patient require analgesia during surgery (diagnosed by increasing heart rate and blood pressure) fentanyl 1mic/kg will be given, and total analgesic consumption will be calculated and recorded.
Measured: Intraoperatively
Heart rate
Heart rate will be recorded every 15 minutes till the end of surgery.
Measured: Till the end of surgery (Up to 2 hours)
Mean arterial blood pressure
Mean arterial blood pressure will be recorded every 15 minutes till the end of surgery.
Measured: Till the end of surgery (Up to 2 hours)
Time of each block
Time of each block will be recorded from using ultrasound probe till injection of local anaesthetic
Measured: Intraoperatively
Sedation score
Sedation score will be recorded at 0, 15 min ,30 min postoperative 0=no sedation (wide awake).
=slightly sedated (easy to arouse) 2=moderately sedated(easy to arouse but cannot stay awake) 3=heavy sedated (difficult to arouse)
Measured: 24 hours postoperatively
Time to first rescue analgesia
Time to first rescue analgesia will be recorded from the end of surgery till first dose of morphine administrated.
Measured: 24 hours postoperatively
Total morphine consumption
If the pain score more than or equal to 4), opioid (morphine) 0.5 to 1 mg/kg will be given and total dose will be calculated
Measured: 24 hours postoperatively
Incidence of postoperative complications
Incidence of postoperative complications such as hypotension, nausea and vomiting will be recorded.
Measured: 24 hours postoperatively
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Sep 2026
- Study start1 Jan 2025
- Primary completion1 Jun 2026
- Study completion1 Jun 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Quadratus Lumborum BlockStudies of the same condition, open and under way.
- More trials run by Menoufia UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 60 participants (actual)
Sponsor and investigators
- Lead sponsor
- Menoufia University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ahmed Hassan Ahmed Tawfeek, Menoufia University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07850596
- Sponsor's protocol ID
- 12/2024 ANET 32
- Status last verified
- Sep 2026
- First submitted
- 23 Sep 2026
- Last updated
- 30 Sep 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
Study at a glance
From the registry record, last updated by the sponsor on 30 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparing Quadratus Lumborum Block, Transversus Abdominis Plane Block, and Erector Spinae Block in Pediatric Abdominal Surgery
- ClinicalTrials.gov ID
- NCT07850596
- Acronym / sponsor ID
- 12/2024 ANET 32
- Conditions
- Quadratus Lumborum Block, Transversus Abdominis Plane Block, Erector Spinae Plane Block, Pediatric, Abdominal Surgery
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 60 participants (actual)
- Lead sponsor
- Menoufia UniversityUniversity, hospital or other
- Study start
- 1 Jan 2025 (actual)
- Primary completion
- 1 Jun 2026 (actual)
- Study completion
- 1 Jun 2026 (actual)
- First posted
- 30 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study is to compare the analgesic efficacy and safety of Quadratus Lumborum (QL), Transversus Abdominis Plane (TAP), and Erector Spinae Plane (ESP) blocks in pediatric abdominal surgery.
Detailed description
Advances in perioperative care of children continue to be made with increasing evidence-based practice for postoperative analgesia. However, moderate to severe pain is still experienced by up to 40% of hospitalized children and specific high-risk populations or types of surgery continue to present challenges.
Transversus abdominis plane (TAP) block involves the injection of local anesthesia (LA) in between the transversus abdominis (TA) and internal oblique (IO) muscles.
The Erector Spinae Plane (ESP) block is most often performed using an in-plane ultrasound-guided technique. It is a paraspinal fascial plane block in which the needle placement is between the erector spinae muscle and the thoracic transverse processes, and a local anesthetic is administered, blocking the dorsal and ventral rami of the thoracic and abdominal spinal nerves.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| QL Group | Experimental | Drug: Quadratus lumborum (QL) blockPatients received quadratus lumborum (QL) block with bupivacaine 0.25% (0.5 ml/kg) + dexmedetomidine 0.5 mcg/kg. |
| TAP group | Experimental | Drug: Transversus abdominis plane (TAP) blockPatients received transversus abdominis plane (TAP) block with bupivacaine 0.25% (0.5 ml/kg) + dexmedetomidine 0.5 mcg/kg |
| ES Group | Experimental | Drug: Erector spinae plane (ESP) blockPatients received erector spinae plane (ESP) block with bupivacaine 0.25% (0.5 ml/kg) + dexmedetomidine 0.5 mcg/kg. |
Who may qualify
- Ages
- 3 to 12 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (4 listed)
- Children aged from 3 to12 years.
- Both sexes.
- American Society of Anesthesiologists (ASA) Physical Status I-II.
- Scheduled for pediatric abdominal surgery.
Key exclusion criteria (5 listed)
- Allergy or contraindication to bupivacaine or dexmedetomidine.
- Coagulopathy.
- Local infection at the site of the block.
- Neurological or psychiatric disorders affecting pain perception.
- Refusal of the regional technique by parents/guardians.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Quadratus lumborum (QL) blockAlso: Bupivacaine 0.25% (0.5 ml/kg) + dexmedetomidine 0.5 mcg/kgPatients received quadratus lumborum (QL) block with bupivacaine 0.25% (0.5 ml/kg) + dexmedetomidine 0.5 mcg/kg. | Drug | QL Group |
| Transversus abdominis plane (TAP) blockAlso: Bupivacaine 0.25% (0.5 ml/kg) + dexmedetomidine 0.5 mcg/kgPatients received transversus abdominis plane (TAP) block with bupivacaine 0.25% (0.5 ml/kg) + dexmedetomidine 0.5 mcg/kg. | Drug | TAP group |
| Erector spinae plane (ESP) blockAlso: Bupivacaine 0.25% (0.5 ml/kg) + dexmedetomidine 0.5 mcg/kgPatients received erector spinae plane (ESP) block with bupivacaine 0.25% (0.5 ml/kg) + dexmedetomidine 0.5 mcg/kg. | Drug | ES Group |
Primary outcome
Degree of pain
Time frame: 24 hours postoperatively
Degree of pain will be assessed using Wong-Baker FACES for the first 24 hours postoperative at 4, 8,12,16 and 24 hours postoperatively. Wong-Baker FACES Pain Scale, which utilizes a series of 6 faces increasing in pain severity may be used to facilitate communication and assist in pain assessment .
8 secondary outcomes
Total fentanyl consumption
Time frame: Intraoperatively
Heart rate
Time frame: Till the end of surgery (Up to 2 hours)
Mean arterial blood pressure
Time frame: Till the end of surgery (Up to 2 hours)
Time of each block
Time frame: Intraoperatively
Sedation score
Time frame: 24 hours postoperatively
Time to first rescue analgesia
Time frame: 24 hours postoperatively
Total morphine consumption
Time frame: 24 hours postoperatively
Incidence of postoperative complications
Time frame: 24 hours postoperatively
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Sep 2026.
- Individual participant dataSharing planned: Yes. The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
Related trials for Quadratus Lumborum Block
Recruiting
Lateral QL Block vs Intrathecal Morphine for Cesarean Section
Anesthesia, Postoperative Pain
Recruiting
Ultrasound-guided Quadratus Lumborum Block Versus Erector Spinae Plane Block for Postoperative Analgesia in Children Undergoing Elective Open Lower Abdominal Surgeries
Bilateral Inguinal Hernia Repair, Open Upper Abdominal Surgeries
Not yet recruiting
PQLB vs TFPB in HALDN
Analgesia, Donor Nephrectomy
Active, not recruitingPhase 2
Repeat or Single Quadratus Lumborum Block for the Reduction of Opioid Prescriptions After Surgery in Retroperitoneal Sarcoma Patients ("RESQU-SARC" Trial)
Retroperitoneal Sarcoma
Not yet recruiting
Quadratus Lumborum Block for Iliac Bone Harvest in Pediatric Cleft Alveolus Repair
Cleft Lip Palate
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Quadratus lumborum (QL) block, Transversus abdominis plane (TAP) block and Erector spinae plane (ESP) block in people with Quadratus Lumborum Block and Transversus Abdominis Plane Block, run by Menoufia University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 30 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Degree of pain (time frame: 24 hours postoperatively). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Sep 2026.